The company said on Thursday that the Lly.N experimental pill of Elli Lily reduced the weight of about 8% at the highest dose and reduced blood sugar in type 2 diabetes patients in a late phase testing.

The stocks jumped 13.7% as a long-awaited test results, first of several people on the bullet, orflipron raised hopes of an effective and easy-to-use treatment, which reached the market dominated by weight-loss injection.

Lily was set to add $ 90 billion to its market capitalization, if there is a benefit.

Many companies around the world are developing weight loss pills, a more convenient option for injections, it is estimated that the sale of obesity treatment may be $ 150 billion in the coming years. The data helps the lily draw forward in the race for effective oral drugs that can compete with the injection.

Lily also said that Orforglipron’s safety profile was in line with other drugs related to the class of weight-loss remedies known as GLP-1s, which removes some concerns on the possible stumbling block for sale.

“Data is luxurious from a efficacy point of view,” the Chief Operating Officer of Kevin Gad, Bahl and Genor said, who owns Lily’s shares.

Lily said it would report data from another test for the bullet for weight management in the year later. It is planning to file for approval with global regulators for weight loss for diabetes by the end of this year and next year.

“While this test is very good alone, it is very well for their testing in obese patients,” Ged said.

The late-stage trial found that drugs between 13% and 18% of patients experienced nausea during the dose, while compared to 2% on the placebo. The rate of diarrhea was 19% to 26% and vomiting was 5% to 14%.

BMO Capital Market analyst Ivan Segerman said, “With some concern of nausea and rising rates of vomiting in today’s readouts, these results strongly validate the tolerant profile of the orflipron.”

On Monday, pfizer pffe.ndiscontine, after the development of its experimental weight loss, experienced a test patient after the development of danuglipron, experienced a potentially drug-inspired liver injury to the patient, which was resolved after the drug was shut down.

Lily said no liver -related security signs were seen in its testing.

The company said that 8% of patients stopped treatment due to adverse events at the highest dose of Orflipron.

The level of HBA1C, a measure of blood sugar over time, fell from 1.3% to 1.6% on average during the dose.

TD Coven analysts recently said in a research note, “Rough Bar” for Orforglipron Testing had a 2%HBA1C lower, 7%weight loss and a dissection rate of 9%.

After 40 weeks of treatment in multi-dose trials, Lily said that once-the-world orforglipron showed 4.7% body weight loss, 6.1% with 12 mg and 7.9% with 36 mg. Patients were lost 1.6%on the placebo.

Data of rival Novo Nordisk’s Novob.co’s mid-stage trial came down from the market expectations last year. Novo’s shares slipped 1%, while small drug developer Viking Therapeutics Vktx.o had 7%below.

Easily manufactured

Lily said that it was confident of its ability to launch Orforglipron worldwide without lack of supply when it was approved. In February, the company recorded $ 550 million related to the drug list in its financial statements, shown in a filing.

The company currently injectable Tirzepatide- The treatment of its diabetes drug mounjaro and obesity sells active ingredients in Zepbound-which mimic the natural peptide hormone GLP-1 and GIP.

Orforglipron also targets GLP-1, but unlike hormone-pulled peptides, including ozempic and wegovy of Novo, it is a synthetic small molecule drug.

Experimental pills such as orforglipron may mean extensive access to effective weight loss options because manufacturing is simple.